https://www.pharmaradar360.com/article/rolling-with-the-waves-ac90c33b7cf09730PharmaRadar360en2026-09-16T12:00:00.000ZRolling with the waveshttps://www.pharmaradar360.com/article/sling-therapeutics-announces-first-patients-dosed-in-global-phase-3-orbit-pivota-d75552e00382cd47PharmaRadar360en2026-09-16T11:05:00.000ZSling Therapeutics Announces First Patients Dosed in Global Phase 3 ORBIT Pivotal Trial of Linsitinib for Thyroid Eye Diseasehttps://www.pharmaradar360.com/article/guidance-national-patient-safety-alert-supporting-information-patient-hoists-and-481832dd1483a5a5PharmaRadar360en2026-09-16T11:04:57.000ZGuidance: National Patient Safety Alert Supporting Information. Patient hoists and slings: incidents and case examples.https://www.pharmaradar360.com/article/national-patient-safety-alert-patient-hoists-and-slings-all-types-risk-of-death-96b745c6c3886211PharmaRadar360en2026-09-16T11:01:57.000ZNational Patient Safety Alert: Patient hoists and slings (all types): risk of death and serious harm from falls (NatPSA/2026/005/MHRA)https://www.pharmaradar360.com/article/sling-gets-123m-for-phase-3-trial-of-ex-astellas-drug-in-thyroid-eye-disease-3e28cc7677d34261PharmaRadar360en2026-09-16T11:00:00.000ZSling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye diseasehttps://www.pharmaradar360.com/article/idexx-laboratories-acquires-covetai-to-advance-veterinary-workflow-intelligence-81cfc6189054a50dPharmaRadar360en2026-09-16T11:00:00.000ZIDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligencehttps://www.pharmaradar360.com/article/la-aemps-informa-de-la-actualizacion-de-la-informacion-de-seguridad-de-los-medic-9860b82efb555986PharmaRadar360en2026-09-16T10:59:13.000ZLa AEMPS informa de la actualización de la información de seguridad de los medicamentos veterinarios que contienen fenobarbitalhttps://www.pharmaradar360.com/article/bristol-myers-squibb-announces-dividend-1d1e3cf8ca63c361PharmaRadar360en2026-09-16T10:59:00.000ZBristol Myers Squibb Announces Dividendhttps://www.pharmaradar360.com/article/la-aemps-recuerda-como-evitar-errores-de-medicacion-por-sobredosificacion-con-vi-e10c84f344062da2PharmaRadar360en2026-09-16T10:47:51.000ZLa AEMPS recuerda cómo evitar errores de medicación por sobredosificación con vitamina Dhttps://www.pharmaradar360.com/article/msd-7b118228b3a79e32PharmaRadar360en2026-09-16T10:43:00.000Zペムブロリズマブ適正使用のお願い_白金系抗悪性腫瘍剤抵抗性の再発卵巣癌（MSD株式会社）https://www.pharmaradar360.com/article/sclerodermia-humanitas-partecipa-alla-giornata-del-ciclamino-ef1b80297605f7c9PharmaRadar360en2026-09-16T10:42:44.000ZSclerodermia: Humanitas partecipa alla Giornata del ciclaminohttps://www.pharmaradar360.com/article/six-neighbourhood-health-trailblazers-to-transform-care-e6da2526d470fa64PharmaRadar360en2026-09-16T10:41:35.000ZSix neighbourhood health trailblazers to transform carehttps://www.pharmaradar360.com/article/tiedonhankinnan-tuokiot-syksylla-2026-2a2791a37b53bdb0PharmaRadar360en2026-09-16T10:31:27.000ZTiedonhankinnan tuokiot syksyllä 2026https://www.pharmaradar360.com/article/medtronic-announces-fda-clearance-for-ligasuretm-ras-maryland-instrument-on-the-adeda03ace33da07PharmaRadar360en2026-09-16T10:30:00.000ZMedtronic announces FDA clearance for LigaSure™ RAS Maryland instrument on the Hugo™ RAS systemhttps://www.pharmaradar360.com/article/should-you-invest-in-the-vaneck-biotech-etf-bbh-03686cfedea3aa38PharmaRadar360en2026-09-16T10:20:02.000ZShould You Invest in the VanEck Biotech ETF (BBH)?https://www.pharmaradar360.com/article/ingrid-zhang-appointed-ceo-of-legend-biotech-amid-mid-september-2026-industry-le-5ed0fa87667a5ca9PharmaRadar360en2026-09-16T10:15:30.000ZIngrid Zhang Appointed CEO of Legend Biotech Amid Mid-September 2026 Industry Leadership Changeshttps://www.pharmaradar360.com/article/tv-drug-ads-could-lose-their-website-shortcut-for-risk-details-under-an-fda-rule-bc0a0495d16ec398PharmaRadar360en2026-09-16T10:15:06.000ZTV Drug Ads Could Lose Their Website Shortcut for Risk Details Under an FDA Rule Planned for Decemberhttps://www.pharmaradar360.com/article/9ad3c82bb027f830PharmaRadar360en2026-09-16T10:08:15.000Zペムブロリズマブ（遺伝子組換え）製剤の最適使用推進ガイドライン（卵巣癌）について（厚生労働省）https://www.pharmaradar360.com/article/beyond-admet-ai-for-medicines-safety-stakeholder-survey-62ff7205a99e26f8PharmaRadar360en2026-09-16T10:08:02.000ZBeyond ADMET: AI for medicines safety stakeholder surveyhttps://www.pharmaradar360.com/article/charite-warnt-vor-personalabbau-und-schlechterer-patientenversorgung-954f5acc34729d49PharmaRadar360en2026-09-16T10:07:38.000ZCharité warnt vor Personalabbau und schlechterer Patientenversorgunghttps://www.pharmaradar360.com/article/8f0cd19707f1caf3PharmaRadar360en2026-09-16T10:06:46.000Zチスレリズマブ（遺伝子組換え）製剤の最適使用推進ガイドライン（上咽頭癌）の作成及び最適使用推進ガイドライン（食道癌及び胃癌）の一部改正について（厚生労働省）https://www.pharmaradar360.com/article/775198a373c05713PharmaRadar360en2026-09-16T10:05:06.000Zトボラフェニブ製剤の使用に当たっての留意事項について（厚生労働省）https://www.pharmaradar360.com/article/4644adfcfbaf2ab9PharmaRadar360en2026-09-16T10:03:40.000Zミルベツキシマブ ソラブタンシン（遺伝子組換え）製剤の使用に当たっての留意事項について（厚生労働省）https://www.pharmaradar360.com/article/ctt-pharma-corporate-updates-7cb9f05535b4eb81PharmaRadar360en2026-09-16T10:00:03.000ZCTT Pharma Corporate Updateshttps://www.pharmaradar360.com/article/digitaler-zwilling-soll-brustkrebspravention-individueller-machen-65208fd48426370bPharmaRadar360en2026-09-16T09:54:27.000ZDigitaler Zwilling soll Brustkrebsprävention individueller machenhttps://www.pharmaradar360.com/article/ers-2026-obesity-an-independent-obstruction-to-biologic-treated-asthma-8fe9aca8139f27b2PharmaRadar360en2026-09-16T09:44:39.000ZERS 2026: obesity, an independent obstruction to biologic-treated asthmahttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-good-clinical-practice-inspections-a1362df4adb5e02bPharmaRadar360en2026-09-16T09:36:23.000ZClinical trials for medicines: Good clinical practice inspectionshttps://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-de-uso-humano-de-septiembre-de-2026-cf9a2cb6077912c0PharmaRadar360en2026-09-16T09:32:00.000ZReunión del Comité de Medicamentos de Uso Humano de septiembre de 2026https://www.pharmaradar360.com/article/trump-administration-shift-puts-this-corner-of-biotech-back-in-favor-9c761ffe135492bbPharmaRadar360en2026-09-16T09:30:00.000ZTrump Administration Shift Puts This Corner of Biotech Back in Favorhttps://www.pharmaradar360.com/article/kim-yong-min-named-2026-jw-sungcheon-award-recipient-85a5f990849a0bc3PharmaRadar360en2026-09-16T09:27:13.000ZKim Yong-min Named 2026 JW Sungcheon Award Recipienthttps://www.pharmaradar360.com/article/daewoong-pharmaceutical-wins-2026-national-contribution-award-05149f7f49635776PharmaRadar360en2026-09-16T09:27:00.000ZDaewoong Pharmaceutical Wins 2026 National Contribution Awardhttps://www.pharmaradar360.com/article/kpbma-holds-korea-thailand-pharmaceutical-forum-in-bangkok-ec594cbe6f8df10bPharmaRadar360en2026-09-16T09:26:59.000ZKPBMA Holds Korea-Thailand Pharmaceutical Forum in Bangkokhttps://www.pharmaradar360.com/article/fda-holds-public-hearing-on-psychedelic-drugs-as-trump-driven-push-gathers-pace-c37ed3be97b94076PharmaRadar360en2026-09-16T09:25:38.000ZFDA holds public hearing on psychedelic drugs as Trump-driven push gathers pacehttps://www.pharmaradar360.com/article/gsk-s-us-750-million-cancer-drug-deal-highlights-china-s-rise-as-biotech-player-019202f18c332040PharmaRadar360en2026-09-16T09:14:57.000ZGSK’s US$750 million cancer drug deal highlights China’s rise as biotech playerhttps://www.pharmaradar360.com/article/how-ai-is-reshaping-the-cdmo-sponsor-relationship-dbb6c49855c23d14PharmaRadar360en2026-09-16T09:10:04.000ZHow AI Is Reshaping the CDMO-Sponsor Relationshiphttps://www.pharmaradar360.com/article/domestic-pharmaceutical-and-bio-stocks-which-are-considered-representative-growt-3fc642a021ab05a4PharmaRadar360en2026-09-16T08:47:06.000ZDomestic pharmaceutical and bio stocks, which are considered representative growth industries alonghttps://www.pharmaradar360.com/article/korea-establishes-public-private-pharmaceutical-industry-innovation-council-647569a7800a757dPharmaRadar360en2026-09-16T08:44:34.000ZKorea establishes public-private pharmaceutical industry innovation councilhttps://www.pharmaradar360.com/article/ascendis-regains-obesity-rights-as-novo-exits-monthly-glp-1-deal-cf9dc0b84009e824PharmaRadar360en2026-09-16T08:41:46.000ZAscendis regains obesity rights as Novo exits monthly GLP-1 dealhttps://www.pharmaradar360.com/article/helsinki-animal-law-seminar-xin-zheng-28-10-2026-b66334489694a403PharmaRadar360en2026-09-16T08:36:10.000ZHelsinki Animal Law Seminar: Xin Zheng 28.10.2026https://www.pharmaradar360.com/article/meddra-29-1-e37560fd41624dadPharmaRadar360en2026-09-16T08:33:10.000ZMedDRA 29.1https://www.pharmaradar360.com/article/sex-ratios-at-birth-in-the-uk-2019-to-2023-e85b4ee4f5630c49PharmaRadar360en2026-09-16T08:30:04.000ZSex ratios at birth in the UK: 2019 to 2023https://www.pharmaradar360.com/article/migrant-health-country-of-origin-health-protection-advice-712e66654b02af33PharmaRadar360en2026-09-16T08:30:03.000ZMigrant health: country-of-origin health protection advicehttps://www.pharmaradar360.com/article/sex-ratios-at-birth-in-the-uk-2018-to-2022-2e081caa376a5196PharmaRadar360en2026-09-16T08:30:03.000ZSex ratios at birth in the UK: 2018 to 2022https://www.pharmaradar360.com/article/sti-quarterly-surveillance-reports-provisional-data-24f79f77d1898abfPharmaRadar360en2026-09-16T08:30:03.000ZSTI quarterly surveillance reports: provisional datahttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-95d573354d6fb70dPharmaRadar360en2026-09-16T08:30:03.000ZUK Clinical Research Delivery key performance indicatorshttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-august-2026-a91ff0b95960e676PharmaRadar360en2026-09-16T08:30:02.000ZUK Clinical Research Delivery key performance indicators: data to August 2026https://www.pharmaradar360.com/article/bovine-tuberculosis-tb-public-health-management-466209379572520bPharmaRadar360en2026-09-16T08:30:02.000ZBovine tuberculosis (TB): public health managementhttps://www.pharmaradar360.com/article/survey-into-the-radiological-impact-of-the-routine-transport-of-radiopharmaceuti-80b294175a4a0760PharmaRadar360en2026-09-16T08:30:01.000ZSurvey into the Radiological Impact of the Routine Transport of Radiopharmaceuticals in the UKhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-16T08:24:50.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/helsinki-animal-law-seminar-david-john-holroyd-17-9-2026-ea05ec76417c45c4PharmaRadar360en2026-09-16T08:22:31.000ZHelsinki Animal Law Seminar: David John Holroyd 17.9.2026https://www.pharmaradar360.com/article/toward-canonical-helm-representations-for-sequence-level-peptide-registration-d7409182dc2c1913PharmaRadar360en2026-09-16T08:18:27.000ZToward Canonical HELM Representations for Sequence-Level Peptide Registrationhttps://www.pharmaradar360.com/article/9-25-jsmo-kfcr-408a09bcda0795e9PharmaRadar360en2026-09-16T08:09:16.000Z【※申請締め切り：9月25日（金）】JSMO／KFCR＊ 公募型若手研究助成についてhttps://www.pharmaradar360.com/article/a-new-system-enables-the-early-detection-of-drug-induced-liver-toxicities-in-pri-3a721253fe2bd48ePharmaRadar360en2026-09-16T08:00:00.000ZA new system enables the early detection of drug-induced liver toxicities in primary carehttps://www.pharmaradar360.com/article/us-biotech-corefx-chooses-cork-as-its-european-r-d-hq-718cbbd0532ecf2cPharmaRadar360en2026-09-16T07:55:42.000ZUS biotech CoreFX chooses Cork as its European R&D HQhttps://www.pharmaradar360.com/article/wuxi-biologics-named-to-forbes-china-esg-50-list-2026-for-green-crdmo-and-digita-732f52b3717008fcPharmaRadar360en2026-09-16T07:54:09.000ZWuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadershiphttps://www.pharmaradar360.com/article/helsinki-animal-law-seminar-laura-ervo-23-9-2026-27784238907df25bPharmaRadar360en2026-09-16T07:53:26.000ZHelsinki Animal Law Seminar: Laura Ervo 23.9.2026https://www.pharmaradar360.com/article/four-decades-of-discovery-at-embl-2b387676ab26e237PharmaRadar360en2026-09-16T07:48:47.000ZFour decades of discovery at EMBLhttps://www.pharmaradar360.com/article/building-a-clear-picture-of-uk-health-research-funding-5fb0da3202bb024bPharmaRadar360en2026-09-16T07:41:32.000ZBuilding a clear picture of UK health research fundinghttps://www.pharmaradar360.com/article/shinpoong-seeks-phase-3-ind-amendment-for-stroke-drug-sp-8203-7c73c2ad1ef58a01PharmaRadar360en2026-09-16T07:19:15.000ZShinpoong seeks phase 3 IND amendment for stroke drug SP-8203https://www.pharmaradar360.com/article/l-essentiel-de-la-generosite-2025-3705f63f541d6466PharmaRadar360en2026-09-16T07:14:44.000ZL’essentiel de la générosité 2025https://www.pharmaradar360.com/article/ai-is-changing-the-talent-biotech-companies-compete-to-hire-6b1fee41fba14396PharmaRadar360en2026-09-16T07:01:38.000ZAI is changing the talent biotech companies compete to hirehttps://www.pharmaradar360.com/article/unmc-brings-ai-expertise-to-6-million-nsf-crop-resilience-project-806a9377b6c1a0e4PharmaRadar360en2026-09-16T07:00:00.000ZUNMC brings AI expertise to $6 million NSF crop resilience projecthttps://www.pharmaradar360.com/article/more-than-1-500-patients-have-taken-part-in-the-clinic-prehabilitation-program-f8328961b65fbbb2PharmaRadar360en2026-09-16T06:58:00.000ZMore than 1,500 patients have taken part in the Clínic Prehabilitation Programhttps://www.pharmaradar360.com/article/decarolis-named-director-of-sponsored-programs-administration-ff1c9934438d7007PharmaRadar360en2026-09-16T06:56:00.000ZDeCarolis named director of Sponsored Programs Administrationhttps://www.pharmaradar360.com/article/center-for-healthy-living-hosts-open-house-through-sept-24-b8c9d6e946465d6cPharmaRadar360en2026-09-16T06:54:00.000ZCenter for Healthy Living hosts open house through Sept. 24https://www.pharmaradar360.com/article/chri-events-examine-advances-in-pediatric-cancer-brain-tumor-research-6b49e60b0a555f4ePharmaRadar360en2026-09-16T06:52:00.000ZCHRI events examine advances in pediatric cancer, brain tumor researchhttps://www.pharmaradar360.com/article/crb-913-obesity-drug-shows-5-weight-loss-in-phase-1b-trial-3275d98d0fe2e371PharmaRadar360en2026-09-16T06:37:03.000ZCRB-913 Obesity Drug Shows 5% Weight Loss in Phase 1b Trialhttps://www.pharmaradar360.com/article/trutakna-meets-all-endpoints-in-phase-3-iga-nephropathy-trial-final-analysis-b7255873d1b753fbPharmaRadar360en2026-09-16T06:36:59.000ZTRUTAKNA Meets All Endpoints in Phase 3 IgA Nephropathy Trial Final Analysishttps://www.pharmaradar360.com/article/foundationone-cdx-braf-v600-braf-31eefd4b67f97474PharmaRadar360en2026-09-16T06:30:00.000ZFoundationOne CDx がんゲノムプロファイル、BRAF V600変異及びBRAF融合遺伝子陽性の神経膠腫に対するトボラフェニブのコンパニオン診断として承認を取得https://www.pharmaradar360.com/article/chugai-obtains-approval-for-foundationone-cdx-cancer-genomic-profile-as-a-compan-26f849ad79ecca25PharmaRadar360en2026-09-16T06:30:00.000ZChugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Tovorafenib for BRAF V600 Alterations and BRAF Fusion Gene-Positive Gliomahttps://www.pharmaradar360.com/article/zymfentra-xcopri-projected-to-become-korea-s-1st-1-billion-blockbuster-drugs-in-1b9ece210cf9d90aPharmaRadar360en2026-09-16T06:19:22.000ZZymfentra, Xcopri projected to become Korea’s 1st $1 billion blockbuster drugs in 2027https://www.pharmaradar360.com/article/avacta-achieves-clinical-proof-of-mechanism-for-the-next-generation-of-pre-cisio-a3abc4b621039f07PharmaRadar360en2026-09-16T06:02:44.000ZAvacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trialhttps://www.pharmaradar360.com/article/sa-har-vgr-byggt-en-modell-for-specialistlakares-fortbildning-da64b4d7e3b0264fPharmaRadar360en2026-09-16T06:00:52.000ZSå har VGR byggt en modell för specialistläkares fortbildninghttps://www.pharmaradar360.com/article/von-der-krebsdiagnose-ins-olympische-dorf-e577fd9be58a7e87PharmaRadar360en2026-09-16T06:00:03.000ZVon der Krebsdiagnose ins Olympische Dorfhttps://www.pharmaradar360.com/article/legend-biotech-names-new-ceo-96784a8d02bcdd18PharmaRadar360en2026-09-16T05:52:35.000ZLegend Biotech names new CEOhttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-mnov-8-rvty-8-txg-6-tlx-9-sdgr-12-51a2a156d99319e7PharmaRadar360en2026-09-16T05:21:00.000ZBiotech Stocks At 52-Week Highs - MNOV +8%, RVTY +8%, TXG +6%, TLX +9%, SDGR +12%https://www.pharmaradar360.com/article/dengiall-india-s-first-indigenous-dengue-vaccine-could-arrive-by-2027-3fcef4b37a7f1fedPharmaRadar360en2026-09-16T04:34:01.000ZDengiAll: India's first indigenous dengue vaccine could arrive by 2027https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-starts-direct-nyse-share-trading-in-shift-fr-49f9efdcc94f4670PharmaRadar360en2026-09-16T04:24:07.000ZTeva Pharmaceutical Industries (TEVA) Starts Direct NYSE Share Trading In Shift From ADShttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-insider-sale-chief-transformation-o-d2af8d6500810d52PharmaRadar360en2026-09-16T04:19:48.000ZTakeda Pharmaceutical (TAK) Insider Sale: Chief Transformation Ohttps://www.pharmaradar360.com/article/left-ventricular-pacing-associated-cardiomyopathy-revealing-myocardial-vulnerabi-3cc98d06ff440cacPharmaRadar360en2026-09-16T03:58:14.000ZLeft Ventricular Pacing‐Associated Cardiomyopathy Revealing Myocardial Vulnerability in Congenital Complete Heart Blockhttps://www.pharmaradar360.com/article/global-covid-19-tracker-b43544edf907cec3PharmaRadar360en2026-09-16T03:58:02.000ZGlobal COVID-19 Trackerhttps://www.pharmaradar360.com/article/leadless-pacemaker-implant-location-as-a-predictor-of-pacing-induced-cardiomyopa-3f898d5fd08f03a7PharmaRadar360en2026-09-16T03:52:48.000ZLeadless Pacemaker Implant Location as a Predictor of Pacing Induced Cardiomyopathyhttps://www.pharmaradar360.com/article/alternating-va-intervals-what-is-the-mechanism-eca4f20c1cb4ac08PharmaRadar360en2026-09-16T03:46:22.000ZAlternating VA Intervals, What is the Mechanism?https://www.pharmaradar360.com/article/fuhrendes-biotech-unternehmen-entscheidet-sich-weltweit-fur-veeva-vault-crm-8c0c10dd0f0dba7ePharmaRadar360en2026-09-16T03:45:00.000ZFührendes Biotech-Unternehmen entscheidet sich weltweit für Veeva Vault CRMhttps://www.pharmaradar360.com/article/etfs-investing-in-hangzhou-biotest-biotech-co-ltd-class-a-stocks-fc0b09bee485f86cPharmaRadar360en2026-09-16T03:38:07.000ZETFs Investing in Hangzhou Biotest Biotech Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/fda-suspends-licences-of-mumbai-s-iconic-cafe-mondegar-3-other-eateries-6541d36f26d84549PharmaRadar360en2026-09-16T03:23:11.000ZFDA suspends licences of Mumbai's iconic Cafe Mondegar, 3 other eaterieshttps://www.pharmaradar360.com/article/3-clinical-stage-cancer-stocks-with-pristine-balance-sheets-f682c41718245b06PharmaRadar360en2026-09-16T03:09:59.000Z3 Clinical-Stage Cancer Stocks With Pristine Balance Sheetshttps://www.pharmaradar360.com/article/pharmosa-biopharm-s-inhaled-drug-l606-wins-china-approval-to-launch-global-phase-ac7ff245c1936bfePharmaRadar360en2026-09-16T03:05:00.000ZPharmosa Biopharm's Inhaled Drug L606 Wins China Approval to Launch Global Phase 3 Trial for Pulmonary Hypertensionhttps://www.pharmaradar360.com/article/tenax-therapeutics-ceo-christopher-giordano-acquires-20-087-in-shares-921f29d813284c41PharmaRadar360en2026-09-16T03:01:00.000ZTenax Therapeutics CEO Christopher Giordano acquires $20,087 in shareshttps://www.pharmaradar360.com/article/us-approves-world-s-first-drug-to-treat-muscle-atrophy-in-sma-5dd33ab3b8a374afPharmaRadar360en2026-09-16T02:58:18.000ZUS approves world’s first drug to treat muscle atrophy in SMAhttps://www.pharmaradar360.com/article/cambium-bio-raises-5m-to-fund-pivotal-phase-3-eye-disease-trial-025f102bc09a7c21PharmaRadar360en2026-09-16T02:52:04.000ZCambium Bio raises $5M to fund pivotal Phase 3 eye disease trialhttps://www.pharmaradar360.com/article/etfs-investing-in-guanhao-biotech-co-ltd-class-a-stocks-b31fd0b4dd031d92PharmaRadar360en2026-09-16T02:46:28.000ZETFs Investing in Guanhao Biotech Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/a-50-anos-los-lapices-siguen-escribiendo-y-son-honoris-causa-de-la-unlp-6c7f199371003580PharmaRadar360en2026-09-16T02:14:57.000ZA 50 años, los Lápices siguen escribiendo y son Honoris Causa de la UNLPhttps://www.pharmaradar360.com/article/a-50-anos-de-su-asesinato-rendimos-homenaje-a-sergio-karakachoff-45d9599f7f2a1eccPharmaRadar360en2026-09-16T02:14:50.000ZA 50 años de su asesinato, rendimos homenaje a Sergio Karakachoffhttps://www.pharmaradar360.com/article/distinguiremos-con-el-doctorado-honoris-causa-a-los-militantes-estudiantiles-de-629241cb090f6c8ePharmaRadar360en2026-09-16T02:14:28.000ZDistinguiremos con el Doctorado Honoris Causa a los militantes estudiantiles de La Noche de los Lápiceshttps://www.pharmaradar360.com/article/pharmac-seeks-feedback-on-widening-access-to-febuxostat-for-people-with-gout-3692c364cf534524PharmaRadar360en2026-09-16T02:00:00.000ZPharmac seeks feedback on widening access to febuxostat for people with gouthttps://www.pharmaradar360.com/article/legend-biotech-taps-novartis-veteran-zhang-as-ceo-58cffabf971dd26aPharmaRadar360en2026-09-16T01:55:47.000ZLegend Biotech taps Novartis veteran Zhang as CEOhttps://www.pharmaradar360.com/article/biotech-midweek-pulse-xbi-loses-steam-after-hot-2026-run-here-are-the-stocks-and-7ea3ba7251b2718aPharmaRadar360en2026-09-16T01:51:08.000ZBiotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Nexthttps://www.pharmaradar360.com/article/biotech-midweek-pulse-xbi-loses-steam-after-hot-2026-run-here-are-the-stocks-and-941d72ff3dff7f07PharmaRadar360en2026-09-16T01:51:00.000ZBiotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Nexthttps://www.pharmaradar360.com/article/active-numeracy-welcomes-colleagues-from-tallinn-university-66ce719462cfbd5fPharmaRadar360en2026-09-16T01:41:33.000ZActive Numeracy Welcomes Colleagues from Tallinn Universityhttps://www.pharmaradar360.com/article/scientists-reversed-biological-age-in-older-adults-in-just-4-weeks-738a0a4357926dd9PharmaRadar360en2026-09-16T01:35:54.000ZScientists reversed biological age in older adults in just 4 weekshttps://www.pharmaradar360.com/article/perriello-discusses-biotech-s-future-with-local-leaders-f075c4ce96759b01PharmaRadar360en2026-09-16T01:30:00.000ZPerriello discusses biotech's future with local leadershttps://www.pharmaradar360.com/article/vera-says-phase-3-trutakna-trial-slowed-iga-nephropathy-progression-5e494faeaa8a90adPharmaRadar360en2026-09-16T01:11:26.000ZVera Says Phase 3 Trutakna Trial Slowed IgA Nephropathy Progressionhttps://www.pharmaradar360.com/article/pharmaceutical-executive-survey-finds-emerging-biotech-ceos-increasingly-rely-on-f8dc02c36dd7a25ePharmaRadar360en2026-09-16T00:16:26.000ZPharmaceutical Executive Survey Finds Emerging Biotech CEOs Increasingly Rely on External Advisorshttps://www.pharmaradar360.com/article/legend-biotech-taps-novartis-veteran-zhang-as-ceo-afe8e7e7d5c3f9a6PharmaRadar360en2026-09-16T00:15:45.000ZLegend Biotech taps Novartis veteran Zhang as CEOhttps://www.pharmaradar360.com/article/en-otsuka-pharmaceutical-obtains-marketing-approval-for-enofeed-liquid-for-enter-5c5b3d702f486c51PharmaRadar360en2026-09-16T00:00:00.000ZEN Otsuka Pharmaceutical Obtains Marketing Approval for ENOFEED® Liquid for Enteral Usehttps://www.pharmaradar360.com/article/local-antibody-driven-response-to-anti-pd-1-blockade-c9984854653c1ff1PharmaRadar360en2026-09-16T00:00:00.000ZLocal antibody-driven response to anti-PD-1 blockadehttps://www.pharmaradar360.com/article/ebv-reactivation-priming-of-the-peripheral-immune-system-in-multiple-sclerosis-r-cd6069644ba7186dPharmaRadar360en2026-09-16T00:00:00.000ZEBV reactivation priming of the peripheral immune system in multiple sclerosis relapsehttps://www.pharmaradar360.com/article/sex-specific-biological-aging-clocks-across-organs-and-omics-83fe2665d8ae7b6dPharmaRadar360en2026-09-16T00:00:00.000ZSex-specific biological aging clocks across organs and omicshttps://www.pharmaradar360.com/article/factor-ix-padua-aav-gene-therapy-in-adolescents-with-hemophilia-b-a-phase-1-tria-51c2bc7b509e2f74PharmaRadar360en2026-09-16T00:00:00.000ZFactor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trialhttps://www.pharmaradar360.com/article/liquid-biopsy-for-early-detection-of-pancreatic-ductal-adenocarcinoma-6015e08250c6d78ePharmaRadar360en2026-09-16T00:00:00.000ZLiquid biopsy for early detection of pancreatic ductal adenocarcinomahttps://www.pharmaradar360.com/article/map-of-brain-microproteins-could-offer-new-clues-to-alzheimer-s-disease-8a6aace6330ff9bbPharmaRadar360en2026-09-16T00:00:00.000ZMap of brain ‘microproteins’ could offer new clues to Alzheimer’s diseasehttps://www.pharmaradar360.com/article/ai-companies-must-work-with-the-research-community-to-protect-attribution-e689188a460becf5PharmaRadar360en2026-09-16T00:00:00.000ZAI companies must work with the research community to protect attributionhttps://www.pharmaradar360.com/article/these-bizarre-much-coveted-microbes-are-revealing-the-origins-of-complex-life-ced692299621bcb2PharmaRadar360en2026-09-16T00:00:00.000ZThese bizarre, much-coveted microbes are revealing the origins of complex lifehttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-a2d331d374f943b7PharmaRadar360en2026-09-16T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-bb15ffb56a868eb9PharmaRadar360en2026-09-16T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-ff3ca531de5730cePharmaRadar360en2026-09-16T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-07ffb382cc605b33PharmaRadar360en2026-09-16T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-ed6bb7eb9549f08fPharmaRadar360en2026-09-16T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-7cb7e32ad9131eb5PharmaRadar360en2026-09-16T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-742f3a5e16d17020PharmaRadar360en2026-09-16T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-8589d7753f9a150aPharmaRadar360en2026-09-16T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-65155282926117bbPharmaRadar360en2026-09-16T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-5fcd2c53d1117f58PharmaRadar360en2026-09-16T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-215330e6ed79ad0fPharmaRadar360en2026-09-16T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-b692b9f63b741656PharmaRadar360en2026-09-16T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-d8d78fac298637a5PharmaRadar360en2026-09-16T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-fd8df7af0ffe3d6cPharmaRadar360en2026-09-16T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicare-program-medicare-appeals-adjustment-to-the-amount-in-controversy-thresh-94915c4cbe3169f1PharmaRadar360en2026-09-16T00:00:00.000ZMedicare Program; Medicare Appeals; Adjustment to the Amount in Controversy Threshold Amounts for Calendar Year 2027https://www.pharmaradar360.com/article/medicare-program-public-meeting-for-new-revisions-to-the-healthcare-common-proce-0dc0a936f4b41fa5PharmaRadar360en2026-09-16T00:00:00.000ZMedicare Program; Public Meeting for New Revisions to the Healthcare Common Procedure Coding System (HCPCS) Level II Codinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-047468a183772e00PharmaRadar360en2026-09-16T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/opportunity-to-co-sponsor-events-with-the-office-of-research-integrity-e16a1d817cc2ee30PharmaRadar360en2026-09-16T00:00:00.000ZOpportunity To Co-Sponsor Events With the Office of Research Integrityhttps://www.pharmaradar360.com/article/government-owned-inventions-availability-for-licensing-8cbe3facb1cb1897PharmaRadar360en2026-09-16T00:00:00.000ZGovernment-Owned Inventions; Availability for Licensinghttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-e0e51e61efa854a9PharmaRadar360en2026-09-16T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-request-30-day-public-comment-request-f6ec9d29697e1d9ePharmaRadar360en2026-09-16T00:00:00.000ZAgency Information Collection Request; 30-Day Public Comment Requesthttps://www.pharmaradar360.com/article/order-under-sections-362-and-365-of-the-public-health-service-act-continuing-the-6789f7d61c90e383PharmaRadar360en2026-09-16T00:00:00.000ZOrder Under Sections 362 and 365 of the Public Health Service Act Continuing the Suspension of the Right To Introduce Certain Persons From Countries Where a Quarantinable Communicable Disease Existshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-4931405acdc3599dPharmaRadar360en2026-09-16T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturinghttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-nih-intramural-reporting-of-research-9f712e6427b6b151PharmaRadar360en2026-09-16T00:00:00.000ZProposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form (Office of the Director/Office of Intramural Research)https://www.pharmaradar360.com/article/microbiology-devices-panel-of-the-medical-devices-advisory-committee-notice-of-m-7f94431e812d15ddPharmaRadar360en2026-09-16T00:00:00.000ZMicrobiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencinghttps://www.pharmaradar360.com/article/vill-bana-vag-for-nya-behandlingar-av-hudsjukdomar-123a8d0c9e3c54adPharmaRadar360en2026-09-16T00:00:00.000ZVill bana väg för nya behandlingar av hudsjukdomarhttps://www.pharmaradar360.com/article/okande-cancertrender-bland-unga-vuxna-ecaa398ef104a372PharmaRadar360en2026-09-16T00:00:00.000ZÖkande cancertrender bland unga vuxnahttps://www.pharmaradar360.com/article/ny-avhandling-utvecklar-statistiska-metoder-for-battre-brostcancervard-8eba6cbff21b3a27PharmaRadar360en2026-09-16T00:00:00.000ZNy avhandling utvecklar statistiska metoder för bättre bröstcancervårdhttps://www.pharmaradar360.com/article/ki-starker-positionerna-i-arets-shanghai-amnesrankning-484868928f5a1a0bPharmaRadar360en2026-09-16T00:00:00.000ZKI stärker positionerna i årets Shanghai-ämnesrankninghttps://www.pharmaradar360.com/article/national-institute-on-aging-awards-21-1m-for-cleveland-alzheimer-s-disease-resea-7c0c0070442dcafaPharmaRadar360en2026-09-16T00:00:00.000ZNational Institute on Aging Awards $21.1M for Cleveland Alzheimer’s Disease Research Centerhttps://www.pharmaradar360.com/article/the-mask-of-delirium-uncovering-a-presumed-cardioembolic-stroke-through-comprehe-ef13b4747a34df72PharmaRadar360en2026-09-16T00:00:00.000ZThe Mask of Delirium: Uncovering a Presumed Cardioembolic Stroke Through Comprehensive Clinical Evaluationhttps://www.pharmaradar360.com/article/mitof-an-integrated-ai-framework-for-forecasting-and-structured-reporting-in-cli-92bbf44c143caa6ePharmaRadar360en2026-09-16T00:00:00.000ZMITOF: An Integrated AI Framework for Forecasting and Structured Reporting in Clinical Immunosuppressive Therapy Managementhttps://www.pharmaradar360.com/article/lt-b-gt-anticoagulant-related-nephropathy-associated-with-vitamin-k-antagonists-81cedfa5bb50a11cPharmaRadar360en2026-09-16T00:00:00.000Z&lt;b&gt;Anticoagulant-Related Nephropathy Associated with Vitamin K Antagonists and Direct Oral Anticoagulants: Epidemiology, Pathophysiology, Clinical Features, and Outcomes&lt;/b&gt;https://www.pharmaradar360.com/article/clinical-characteristics-and-surgical-outcomes-of-retroperitoneal-unicentric-cas-afcd2297f84e5ad9PharmaRadar360en2026-09-16T00:00:00.000ZClinical Characteristics and Surgical Outcomes of Retroperitoneal Unicentric Castleman Disease: A Single-Center Retrospective Studyhttps://www.pharmaradar360.com/article/effects-of-transcutaneous-electrical-acupoint-stimulation-on-colonic-spasm-durin-360fb6c6fc59753aPharmaRadar360en2026-09-16T00:00:00.000ZEffects of transcutaneous electrical acupoint stimulation on colonic spasm during colonoscopy: A randomized controlled trialhttps://www.pharmaradar360.com/article/review-of-aligner-materials-and-their-clinical-applications-a-literature-review-393d4d6ab5bd9c14PharmaRadar360en2026-09-16T00:00:00.000ZReview of aligner materials and their clinical applications: A literature reviewhttps://www.pharmaradar360.com/article/engineering-of-ohet72-nanocrystals-into-nanostructured-microparticles-for-pulmon-b1f7a2598f504136PharmaRadar360en2026-09-16T00:00:00.000ZEngineering of OHet72 Nanocrystals into Nanostructured Microparticles for Pulmonary Delivery of a Novel Antitubercular Drug Candidatehttps://www.pharmaradar360.com/article/chia-seed-allergy-emerging-clinical-evidence-molecular-allergens-and-the-unresol-facb4541734c3403PharmaRadar360en2026-09-16T00:00:00.000ZChia Seed Allergy: Emerging Clinical Evidence, Molecular Allergens, and the Unresolved Question of Cross-Reactivityhttps://www.pharmaradar360.com/article/equivocal-dopamine-transporter-imaging-integrating-visual-assessment-quantificat-fc6783a086ee78abPharmaRadar360en2026-09-16T00:00:00.000ZEquivocal Dopamine Transporter Imaging: Integrating Visual Assessment, Quantification, and Clinical Follow-Uphttps://www.pharmaradar360.com/article/neural-interfaces-for-bidirectional-sensory-restoration-in-limb-prostheses-curre-5c6660fd982425f1PharmaRadar360en2026-09-16T00:00:00.000ZNeural Interfaces for Bidirectional Sensory Restoration in Limb Prostheses: Current Evidence and Clinical Translationhttps://www.pharmaradar360.com/article/acute-limb-ischemia-during-pregnancy-a-case-report-and-narrative-review-of-the-l-f51dd976cf886305PharmaRadar360en2026-09-16T00:00:00.000ZAcute Limb Ischemia During Pregnancy: A Case Report and Narrative Review of the Literaturehttps://www.pharmaradar360.com/article/effects-of-botulinum-toxin-injection-on-masticatory-muscle-activity-in-sleep-bru-302744fb35ec2609PharmaRadar360en2026-09-16T00:00:00.000ZEffects of Botulinum Toxin Injection on Masticatory Muscle Activity in Sleep Bruxism: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/in-vivo-comparison-of-laser-fluorescence-near-infrared-transillumination-and-con-4347cb2b342715dbPharmaRadar360en2026-09-16T00:00:00.000ZIn Vivo Comparison of Laser Fluorescence, Near-Infrared Transillumination, and Conventional Methods for Approximal Caries Detectionhttps://www.pharmaradar360.com/article/aging-in-schizophrenia-clinical-biological-and-psychosocial-perspectives-3357f8913b674d08PharmaRadar360en2026-09-16T00:00:00.000ZAging in Schizophrenia: Clinical, Biological, and Psychosocial Perspectiveshttps://www.pharmaradar360.com/article/clinical-outcomes-in-pediatric-acute-lymphoblastic-leukemia-a-retrospective-coho-b454992a5aa3bec2PharmaRadar360en2026-09-16T00:00:00.000ZClinical outcomes in pediatric acute lymphoblastic leukemia: a retrospective cohort study from a tertiary center in Indonesiahttps://www.pharmaradar360.com/article/transcutaneous-auricular-vagus-nerve-stimulation-targets-the-brain-gut-axis-to-t-c7ed69eab8b988b5PharmaRadar360en2026-09-16T00:00:00.000ZTranscutaneous auricular vagus nerve stimulation targets the brain-gut axis to treat functional dyspepsia: a scoping review of clinical evidence and mechanistic researchhttps://www.pharmaradar360.com/article/mafld-is-linked-to-lower-hbv-dna-levels-in-chronic-hepatitis-b-clinical-and-tran-89e3837cbe2b6f2cPharmaRadar360en2026-09-16T00:00:00.000ZMAFLD is linked to lower HBV DNA levels in chronic hepatitis B: clinical and transcriptomic insightshttps://www.pharmaradar360.com/article/interpretable-machine-learning-models-using-early-dynamic-clinical-features-to-p-2f08580acd61747fPharmaRadar360en2026-09-16T00:00:00.000ZInterpretable machine learning models using early dynamic clinical features to predict early hemodynamic stabilization after vasopressor initiation in patients with septic shock: development in MIMIC-IV and external validation in eICUhttps://www.pharmaradar360.com/article/development-and-internal-validation-of-a-clinical-nomogram-for-identifying-lupus-8cf07557b9131fc2PharmaRadar360en2026-09-16T00:00:00.000ZDevelopment and internal validation of a clinical nomogram for identifying lupus nephritis in patients with systemic lupus erythematosushttps://www.pharmaradar360.com/article/roles-of-community-drug-distributors-in-health-and-development-activities-post-o-449965f56fbda972PharmaRadar360en2026-09-16T00:00:00.000ZRoles of community drug distributors in health and development activities post-onchocerciasis elimination in Ugandahttps://www.pharmaradar360.com/article/engineering-the-oxidative-myocardium-ros-responsive-biomaterials-for-precision-c-f850207104621730PharmaRadar360en2026-09-16T00:00:00.000ZEngineering the oxidative myocardium: ROS-responsive biomaterials for precision cardiovascular delivery in ischemia-reperfusion injury and post-infarction remodelinghttps://www.pharmaradar360.com/article/a-framework-of-microbial-genomic-database-for-clinical-metagenomic-pathogen-diag-45db2974831d7577PharmaRadar360en2026-09-16T00:00:00.000ZA framework of Microbial Genomic Database for clinical metagenomic pathogen diagnosis: development and multi-cohort evaluationhttps://www.pharmaradar360.com/article/clinical-outcomes-and-their-relationship-with-tigecycline-exposure-in-critically-fd1c7aa5123cab7ePharmaRadar360en2026-09-16T00:00:00.000ZClinical outcomes and their relationship with tigecycline exposure in critically ill patients with drug resistant infectionshttps://www.pharmaradar360.com/article/toward-standardized-continuous-glucose-monitoring-validation-lessons-from-the-si-d07f20738b0bc797PharmaRadar360en2026-09-16T00:00:00.000ZToward standardized continuous glucose monitoring validation: lessons from the Sinocare iCan i3 accuracy studyhttps://www.pharmaradar360.com/article/the-universal-biocode-framework-2-0-a-philosophical-numerical-integration-of-mul-66d5897507ba8e2ePharmaRadar360en2026-09-16T00:00:00.000ZThe Universal BioCode Framework 2.0: A Philosophical-Numerical Integration of Multi-Omic Data, Spatial Technologies, and Clinical Outcomes for Precision Medicinehttps://www.pharmaradar360.com/article/three-month-clinical-outcomes-and-exploratory-gait-changes-after-intra-articular-4792c080c51d3b2dPharmaRadar360en2026-09-16T00:00:00.000ZThree-Month Clinical Outcomes and Exploratory Gait Changes After Intra- Articular Platelet-Rich Plasma for Mild-to-Moderate Knee Osteoarthritis: A Prospective Single-Arm Studyhttps://www.pharmaradar360.com/article/clinical-outcomes-of-short-versus-long-course-antibiotic-therapy-in-pseudomonas-8d14d9e4f063d84bPharmaRadar360en2026-09-16T00:00:00.000ZClinical Outcomes of Short- Versus Long-Course Antibiotic Therapy in Pseudomonas aeruginosa-Positive Mild-to-Moderate Bronchiectasis Stratified by Day-7 Sputum Bacterial Loadhttps://www.pharmaradar360.com/article/drug-interaction-with-inhibitors-prediction-of-exposure-of-drugs-following-drug-1b93a2c92477e7f9PharmaRadar360en2026-09-16T00:00:00.000ZDrug Interaction with Inhibitors: Prediction of Exposure of Drugs Following Drug-Inhibitor Interaction Based on Molecular Weight Ratiohttps://www.pharmaradar360.com/article/entre-la-pluma-y-el-proceso-b456813cf4482395PharmaRadar360en2026-09-16T00:00:00.000ZEntre la pluma y el procesohttps://www.pharmaradar360.com/article/biliary-duct-invasion-in-colorectal-liver-metastases-prevalence-and-clinicopatho-6fa6ce0eaa4d7609PharmaRadar360en2026-09-16T00:00:00.000ZBiliary Duct Invasion in Colorectal Liver Metastases: Prevalence and Clinicopathologic Correlation in a Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/acute-liver-failure-temporally-associated-with-intensive-consumption-of-plantago-b97af186d1e65650PharmaRadar360en2026-09-16T00:00:00.000ZAcute liver failure temporally associated with intensive consumption of Plantago major tea: A case reporthttps://www.pharmaradar360.com/article/machine-learning-identifies-microbiome-and-clinical-predictors-of-sustained-weig-f676385b82b8952cPharmaRadar360en2026-09-16T00:00:00.000ZMachine learning identifies microbiome and clinical predictors of sustained weight loss following prolonged fastinghttps://www.pharmaradar360.com/article/circumferential-pulmonary-vein-isolation-cpvi-with-adjunctive-linear-ablation-vs-a47b925fa38d3406PharmaRadar360en2026-09-16T00:00:00.000ZCircumferential pulmonary vein isolation (CPVI) with adjunctive linear ablation vs. CPVI alone for long-standing persistent atrial fibrillation (SINUS): study protocol for a prospective, multi-center, randomized controlled trialhttps://www.pharmaradar360.com/article/reproducibility-driven-clinical-translation-of-spatial-multi-omics-in-precision-82d5d75d1a1a0777PharmaRadar360en2026-09-16T00:00:00.000ZReproducibility-driven clinical translation of spatial multi-omics in precision medicinehttps://www.pharmaradar360.com/article/feasibility-and-implementation-of-a-final-year-objective-structured-clinical-exa-ee2af8b9f3f65723PharmaRadar360en2026-09-16T00:00:00.000ZFeasibility and implementation of a final year Objective Structured Clinical Examination (OSCE) in a medical model curriculumhttps://www.pharmaradar360.com/article/neuroanatomical-correlates-of-transdiagnostic-clinical-phenotypes-in-major-depre-4dd2840f07cc0f2aPharmaRadar360en2026-09-16T00:00:00.000ZNeuroanatomical correlates of transdiagnostic clinical phenotypes in major depressive and bipolar disordershttps://www.pharmaradar360.com/article/effect-of-partner-administered-endorphin-massage-before-cesarean-birth-on-preope-788a98637fee02ddPharmaRadar360en2026-09-16T00:00:00.000ZEffect of partner-administered endorphin massage before cesarean birth on preoperative anxiety and pain: a quasi-randomised controlled trialhttps://www.pharmaradar360.com/article/two-year-clinical-outcomes-of-vagus-nerve-stimulation-for-higher-grade-treatment-7df4dbe3f0664ae5PharmaRadar360en2026-09-16T00:00:00.000ZTwo-Year Clinical Outcomes of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depressionhttps://www.pharmaradar360.com/article/post-procedural-angiography-based-physiological-indices-and-clinical-outcomes-af-317af6e3847c728ePharmaRadar360en2026-09-16T00:00:00.000ZPost-Procedural Angiography-Based Physiological Indices and Clinical Outcomes After Drug-Coated Balloon Treatment of In-Stent Restenosishttps://www.pharmaradar360.com/article/the-epistemological-threshold-from-corps-objet-to-nursing-theory-in-the-clinical-fb164486a8f877caPharmaRadar360en2026-09-16T00:00:00.000ZThe Epistemological Threshold: From Corps-Objet to Nursing Theory in the Clinical Maturation of Educatorshttps://www.pharmaradar360.com/article/dose-optimization-or-rescue-interpreting-week-24-disease-control-after-abrocitin-4ca84c39e4415760PharmaRadar360en2026-09-16T00:00:00.000ZDose Optimization or Rescue? Interpreting Week 24 Disease Control After Abrocitinib Dose Modificationhttps://www.pharmaradar360.com/article/the-situated-nature-of-validity-exploring-cultural-dependency-in-clinical-teache-6b769038838f3fabPharmaRadar360en2026-09-16T00:00:00.000ZThe Situated Nature of Validity: Exploring Cultural Dependency in Clinical Teacher Evaluation in Japan—Implications for Global Scholarshiphttps://www.pharmaradar360.com/article/adverse-childhood-experiences-and-cognitive-functional-aging-trajectories-a-nati-5c694f37b4aaf83ePharmaRadar360en2026-09-16T00:00:00.000ZAdverse Childhood Experiences and Cognitive-Functional Aging Trajectories: A Nationally Representative Study in Chinahttps://www.pharmaradar360.com/article/expression-of-concern-regulation-of-the-breast-cancer-stem-cell-phenotype-by-hyp-142cf341eac8a2fdPharmaRadar360en2026-09-16T00:00:00.000ZExpression of Concern: Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factorshttps://www.pharmaradar360.com/article/factor-ix-padua-aav-gene-therapy-in-adolescents-with-hemophilia-b-a-phase-1-tria-caf86e20d800d79dPharmaRadar360en2026-09-16T00:00:00.000ZFactor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trialhttps://www.pharmaradar360.com/article/preliminary-efficacy-with-daraxonrasib-demonstrated-in-ras-mutant-nsclc-c71e341500d43920PharmaRadar360en2026-09-16T00:00:00.000ZPreliminary efficacy with daraxonrasib demonstrated in RAS-mutant NSCLChttps://www.pharmaradar360.com/article/structure-based-drug-design-of-quinoline-cyp8b1-inhibitors-for-the-potential-tre-456543ff4bf951daPharmaRadar360en2026-09-16T00:00:00.000ZStructure-Based Drug Design of Quinoline CYP8B1 Inhibitors for the Potential Treatment of Metabolic Diseasehttps://www.pharmaradar360.com/article/prevalence-of-metabolic-syndrome-among-adult-population-in-pakistan-a-systematic-2d50b0f09c28aafbPharmaRadar360en2026-09-16T00:00:00.000ZPrevalence of Metabolic Syndrome among Adult Population in Pakistan: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/bile-acid-based-therapeutics-recent-advances-in-bile-acid-conjugates-and-derivat-a1c51191c2d63fbfPharmaRadar360en2026-09-16T00:00:00.000ZBile acid-based therapeutics: recent advances in bile acid conjugates and derivativeshttps://www.pharmaradar360.com/article/sinapic-acid-from-plant-biosynthesis-to-translational-prospects-a-critical-revie-a18d856bb31e48c9PharmaRadar360en2026-09-16T00:00:00.000ZSinapic Acid: From Plant Biosynthesis to Translational Prospects — A Critical Review of Phytochemistry, Biosynthesis, Extraction, Analytical Quantification, Preclinical Pharmacology, and Emerging Drug Delivery Strategieshttps://www.pharmaradar360.com/article/trends-of-laponite-clay-mineral-as-an-excipient-in-pharmaceuticals-cosmetics-and-e70dbd0ba7fac1ddPharmaRadar360en2026-09-16T00:00:00.000ZTrends of Laponite® Clay Mineral as an Excipient in Pharmaceuticals, Cosmetics and Medical Devices: Patent Analysishttps://www.pharmaradar360.com/article/prophylactic-and-therapeutic-effects-of-aspirin-in-cancer-2b6c5055ad36bfecPharmaRadar360en2026-09-16T00:00:00.000ZProphylactic and therapeutic effects of aspirin in cancerhttps://www.pharmaradar360.com/article/orthostatic-hypertension-clinical-spectrum-and-gaps-in-knowledge-94d78edfefdc7fcePharmaRadar360en2026-09-16T00:00:00.000ZOrthostatic Hypertension: Clinical Spectrum and Gaps in Knowledgehttps://www.pharmaradar360.com/article/role-of-glycosylated-small-noncoding-rnas-in-tumor-mechanism-function-and-clinic-252270806604a20bPharmaRadar360en2026-09-16T00:00:00.000ZRole of glycosylated small noncoding RNAs in tumor: mechanism, function and clinical significancehttps://www.pharmaradar360.com/article/psychiatric-consultation-outcomes-in-deep-brain-stimulation-candidacy-clinical-a-8ceb7d66de01cabfPharmaRadar360en2026-09-16T00:00:00.000ZPsychiatric consultation outcomes in deep brain stimulation candidacy: clinical and psychosocial correlates from a retrospective cohorthttps://www.pharmaradar360.com/article/efficacy-and-safety-of-seawater-based-nasal-irrigation-on-nasal-congestion-in-in-2bd10283b66ded68PharmaRadar360en2026-09-16T00:00:00.000ZEfficacy and safety of seawater-based nasal irrigation on nasal congestion in infants and toddlers with common cold: a randomized controlled trialhttps://www.pharmaradar360.com/article/a-novel-presenilin-1-variant-p-scp-phe283val-scp-in-early-onset-mild-cognitive-i-afc9f2e92940044ePharmaRadar360en2026-09-16T00:00:00.000ZA Novel Presenilin‐1 Variant (p. <scp>Phe283Val</scp> ) in Early‐Onset Mild Cognitive Impairment With Striatal Amyloid Accumulationhttps://www.pharmaradar360.com/article/stripping-based-approach-for-the-recovery-of-volatile-fatty-acids-from-anaerobic-6145224ecbb3a9b7PharmaRadar360en2026-09-16T00:00:00.000ZStripping‐based approach for the recovery of volatile fatty acids from anaerobic digestion digestate: preliminary experimental investigations and modellinghttps://www.pharmaradar360.com/article/impact-of-circumferential-calcification-and-acquired-minimum-lumen-area-on-1-yea-9e1ca065c87ef7a8PharmaRadar360en2026-09-16T00:00:00.000ZImpact of Circumferential Calcification and Acquired Minimum Lumen Area on 1‐Year Primary Patency After Drug‐Coated Balloon Angioplasty for Femoropopliteal Lesionshttps://www.pharmaradar360.com/article/artificial-intelligence-guided-phenotypic-drug-repurposing-against-i-streptococc-47fae4e027c30a26PharmaRadar360en2026-09-16T00:00:00.000ZArtificial Intelligence‐Guided Phenotypic Drug Repurposing Against <i>Streptococcus pneumoniae</i>https://www.pharmaradar360.com/article/vaneck-pharmaceutical-etf-vs-vaneck-biotech-etf-which-fund-is-better-for-drug-in-b9bc71be1ddc8dc6PharmaRadar360en2026-09-15T23:44:00.000ZVanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?https://www.pharmaradar360.com/article/tom-perriello-joins-biotech-leaders-in-discussing-the-future-of-the-industry-13f2b46b03a0976aPharmaRadar360en2026-09-15T22:46:00.000ZTom Perriello joins biotech leaders in discussing the future of the industryhttps://www.pharmaradar360.com/article/recon-experts-press-fda-to-set-safety-access-standards-for-psychedelic-drugs-gsk-3665e6a8d1db5683PharmaRadar360en2026-09-15T22:34:00.000ZRecon: Experts press FDA to set safety, access standards for psychedelic drugs; GSK to shut German vaccine factory due to low demandhttps://www.pharmaradar360.com/article/fda-hearing-on-psychedelic-medicine-reveals-a-field-divided-on-the-road-to-appro-66ed1628669a29acPharmaRadar360en2026-09-15T22:11:13.000ZFDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approvalhttps://www.pharmaradar360.com/article/tallinn-visits-helsinki-collaboration-between-two-sen-research-communities-d26e6a05663f98e7PharmaRadar360en2026-09-15T22:01:55.000ZTallinn Visits Helsinki: Collaboration between Two SEN Research Communitieshttps://www.pharmaradar360.com/article/21-cfr-part-820-qmsr-what-changed-and-how-to-comply-bdd37ce77b959bdePharmaRadar360en2026-09-15T21:55:34.000Z21 CFR Part 820 (QMSR): What Changed and How to Complyhttps://www.pharmaradar360.com/article/australian-biotech-sues-grail-over-multi-cancer-blood-test-c5040893d12c96e8PharmaRadar360en2026-09-15T21:21:33.000ZAustralian biotech sues Grail over multi-cancer blood testhttps://www.pharmaradar360.com/article/psychedelic-drug-trials-patient-safety-take-spotlight-at-fda-hearing-3c3aa5cc1f9daeffPharmaRadar360en2026-09-15T20:56:55.000ZPsychedelic Drug Trials, Patient Safety Take Spotlight at FDA Hearinghttps://www.pharmaradar360.com/article/capa-management-5-elements-of-an-effective-capa-system-0ca14dd7350e28abPharmaRadar360en2026-09-15T20:38:00.000ZCAPA Management: 5 Elements of an Effective CAPA Systemhttps://www.pharmaradar360.com/article/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-aardvark-thera-528a6f2157cc4e25PharmaRadar360en2026-09-15T20:27:00.000ZPomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARDhttps://www.pharmaradar360.com/article/legend-biotech-taps-novartis-veteran-zhang-as-ceo-2e29865224852ac9PharmaRadar360en2026-09-15T20:26:53.000ZLegend Biotech taps Novartis veteran Zhang as CEOhttps://www.pharmaradar360.com/article/legend-biotech-corporation-e4e73548800141d8PharmaRadar360en2026-09-15T20:26:53.000ZLegend Biotech Corporationhttps://www.pharmaradar360.com/article/novartis-veteran-ingrid-zhang-tapped-to-lead-legend-biotech-0e9909e2fc0033edPharmaRadar360en2026-09-15T20:04:40.000ZNovartis veteran Ingrid Zhang tapped to lead Legend Biotechhttps://www.pharmaradar360.com/article/sanofi-cheplapharm-form-strategic-partnership-pharmexec-251834663ca8ba0dPharmaRadar360en2026-09-15T19:48:59.000ZSanofi & Cheplapharm Form Strategic Partnership | PharmExechttps://www.pharmaradar360.com/article/gsk-bolsters-oncology-pipeline-with-750m-chimagen-tce-deal-826c82260bc41af2PharmaRadar360en2026-09-15T19:48:46.000ZGSK bolsters oncology pipeline with $750m Chimagen TCE dealhttps://www.pharmaradar360.com/article/if-you-name-it-you-can-tame-it-102ad926a350c9a5PharmaRadar360en2026-09-15T19:35:06.000ZIf you name it, you can tame ithttps://www.pharmaradar360.com/article/our-biotech-etf-pick-is-on-a-roll-there-s-plenty-of-reasons-to-stay-bullish-bc9825efc83646e6PharmaRadar360en2026-09-15T19:29:00.000ZOur Biotech ETF Pick Is on a Roll. There’s Plenty of Reasons to Stay Bullish.https://www.pharmaradar360.com/article/how-ai-is-rewriting-the-rules-for-medicine-and-biotech-in-mass-2641f3cd0e60363aPharmaRadar360en2026-09-15T19:19:32.000ZHow AI is rewriting the rules for medicine and biotech in Mass.https://www.pharmaradar360.com/article/montana-s-giving-the-biotech-industry-sweeping-authority-to-sell-unapproved-drug-2190e459be361d76PharmaRadar360en2026-09-15T19:19:00.000ZMontana’s giving the biotech industry sweeping authority to sell unapproved drugshttps://www.pharmaradar360.com/article/toward-canonical-helm-representations-for-sequence-level-peptide-registration-1daac6a9a95951c5PharmaRadar360en2026-09-15T19:02:53.000ZToward Canonical HELM Representations for Sequence-Level Peptide Registrationhttps://www.pharmaradar360.com/article/ori-biotech-lands-10-year-120m-commercial-cell-therapy-manufacturing-deal-7056cd82be379659PharmaRadar360en2026-09-15T18:58:15.000ZOri Biotech Lands 10-Year, $120M Commercial Cell Therapy Manufacturing Dealhttps://www.pharmaradar360.com/article/raising-kids-in-a-digital-world-with-less-fear-more-strategy-9c6c928fc1781741PharmaRadar360en2026-09-15T18:54:08.000ZRaising kids in a digital world with less fear, more strategyhttps://www.pharmaradar360.com/article/three-uconn-school-of-pharmacy-alumni-will-be-recognized-at-the-2026-uconn-schoo-1fefb87b25eb0c92PharmaRadar360en2026-09-15T18:51:18.000ZThree UConn School of Pharmacy Alumni will be recognized at the 2026 UConn School of Pharmacy & Pharmaceutical Sciences Alumni Awardshttps://www.pharmaradar360.com/article/russian-strikes-damaged-ukrainian-pharma-hub-logistic-center-steel-plant-killing-853d697821a8fef7PharmaRadar360en2026-09-15T18:50:28.000ZRussian Strikes Damaged Ukrainian Pharma Hub, Logistic Center, Steel Plant, Killing 2https://www.pharmaradar360.com/article/oric-oric-doubles-down-on-prostate-cancer-with-phase-3-launch-f66cc21c17ead25dPharmaRadar360en2026-09-15T18:28:54.000ZORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launchhttps://www.pharmaradar360.com/article/intermountain-health-and-west-valley-city-unveil-plans-for-major-new-medical-cam-0c88cab57bef4e35PharmaRadar360en2026-09-15T18:15:39.000ZIntermountain Health and West Valley City Unveil Plans for Major New Medical Campus That Will Significantly Enhance Access to Care for Residents in West Salt Lake Countyhttps://www.pharmaradar360.com/article/kff-tracker-america-first-mou-bilateral-global-health-agreements-e54c4408e718605bPharmaRadar360en2026-09-15T18:12:59.000ZKFF Tracker: America First MOU Bilateral Global Health Agreementshttps://www.pharmaradar360.com/article/drugstore-museum-hooks-visitors-with-old-timey-treats-and-pharmaceutical-history-61f4e7444ae094a1PharmaRadar360en2026-09-15T18:12:21.000ZDrugstore museum hooks visitors with old-timey treats and pharmaceutical historyhttps://www.pharmaradar360.com/article/iq-oq-pq-explained-2026-process-validation-guide-e94487244e4749c5PharmaRadar360en2026-09-15T18:01:13.000ZIQ, OQ, PQ Explained: 2026 Process Validation Guidehttps://www.pharmaradar360.com/article/29a-convocatoria-del-fondo-regional-para-proyectos-de-cooperacion-triangular-002ec6ed68b7ec77PharmaRadar360en2026-09-15T17:55:11.000Z29ª Convocatoria del Fondo Regional para proyectos de Cooperación Triangularhttps://www.pharmaradar360.com/article/lonza-to-build-new-pharmaceutical-manufacturing-facility-in-bend-49861c4b3456de31PharmaRadar360en2026-09-15T17:46:12.000ZLonza to Build New Pharmaceutical Manufacturing Facility in Bendhttps://www.pharmaradar360.com/article/iso-14971-risk-management-for-medical-devices-2026-guide-219c6abcfbfaa90dPharmaRadar360en2026-09-15T17:42:22.000ZISO 14971 Risk Management for Medical Devices: 2026 Guidehttps://www.pharmaradar360.com/article/exclusive-ai-biotech-isomorphic-labs-is-not-slowing-down-exec-says-a015998a3add4c6bPharmaRadar360en2026-09-15T17:26:00.000ZExclusive / AI biotech Isomorphic Labs is not slowing down, exec sayshttps://www.pharmaradar360.com/article/pbe-vs-rsph-is-a-biotech-etf-or-equal-weight-healthcare-etf-the-better-choice-fo-98e58d141079b271PharmaRadar360en2026-09-15T17:23:00.000ZPBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors?https://www.pharmaradar360.com/article/drug-safety-communications-9827bff184a3fa3aPharmaRadar360en2026-09-15T17:21:48.000ZDrug Safety Communicationshttps://www.pharmaradar360.com/article/could-you-survive-the-oregon-trail-an-emergency-medicine-doctor-offers-tips-on-h-c88c6bb91a76a3f1PharmaRadar360en2026-09-15T17:17:06.000ZCould You Survive The Oregon Trail? An Emergency Medicine Doctor Offers Tips On How To Not Die In The Great Outdoorshttps://www.pharmaradar360.com/article/as-trump-backs-psychedelics-research-fda-weighs-safety-and-access-standards-5288c954840a3a9aPharmaRadar360en2026-09-15T17:11:00.000ZAs Trump backs psychedelics research, FDA weighs safety and access standardshttps://www.pharmaradar360.com/article/clinical-trials-sellas-life-sciences-39fff20cebd8d953PharmaRadar360en2026-09-15T17:08:34.000ZClinical Trials - Sellas Life Scienceshttps://www.pharmaradar360.com/article/cordis-project-personalized-disease-prediction-and-prevention-in-chronic-inflamm-dc682383b7c99e54PharmaRadar360en2026-09-15T17:06:14.000ZCORDIS project: Personalized disease prediction and prevention in chronic inflammatory disordershttps://www.pharmaradar360.com/article/cordis-project-bridging-gaps-in-mental-health-support-a-comprehensive-european-s-9e9a95fdd93723afPharmaRadar360en2026-09-15T17:06:13.000ZCORDIS project: Bridging Gaps in Mental Health Support: A Comprehensive European Strategyhttps://www.pharmaradar360.com/article/genfit-plans-phase-2-liver-failure-trial-after-acquiring-immunomodulator-from-in-a5b612c6084d9b58PharmaRadar360en2026-09-15T17:00:00.000ZGenfit plans Phase 2 liver failure trial after acquiring immunomodulator from Inotremhttps://www.pharmaradar360.com/article/external-data-accelerator-your-standards-first-team-and-technology-for-conforman-d396193ebbd13297PharmaRadar360en2026-09-15T16:57:45.000ZExternal Data Accelerator: Your standards-first team and technology for conformant vendor datahttps://www.pharmaradar360.com/article/iso-13485-explained-medical-device-qms-requirements-2026-6706a1c61f947803PharmaRadar360en2026-09-15T16:54:17.000ZISO 13485 Explained: Medical Device QMS Requirements (2026)https://www.pharmaradar360.com/article/beyond-cost-avoidance-advancing-unit-level-pharmaceutical-economics-in-health-sy-a6670ef0c8744a77PharmaRadar360en2026-09-15T16:53:21.000ZBeyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systemshttps://www.pharmaradar360.com/article/lineberger-building-technology-base-for-better-cancer-vaccines-9117c3b12ec6706dPharmaRadar360en2026-09-15T16:47:28.000ZLineberger building technology base for better cancer vaccineshttps://www.pharmaradar360.com/article/pbe-vs-rsph-is-a-biotech-etf-or-equal-weight-healthcare-etf-the-better-choice-fo-8d536855447ea87fPharmaRadar360en2026-09-15T16:43:33.000ZPBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors?https://www.pharmaradar360.com/article/vera-therapeutics-vera-stock-surges-following-promising-origin3-trial-results-0dcc1dff0d8c2ccfPharmaRadar360en2026-09-15T16:37:40.000ZVera Therapeutics (VERA) Stock Surges Following Promising ORIGIN3 Trial Resultshttps://www.pharmaradar360.com/article/must-see-museums-the-heritage-gallery-f8ae478aab63fcf2PharmaRadar360en2026-09-15T16:34:39.000ZMust See Museums: The Heritage Galleryhttps://www.pharmaradar360.com/article/minnesota-healthcare-providers-detail-harm-to-patients-from-operation-metro-surg-1431dfd58da5f22fPharmaRadar360en2026-09-15T16:34:17.000ZMinnesota healthcare providers detail harm to patients from Operation Metro Surgehttps://www.pharmaradar360.com/article/minnesota-private-well-owners-are-largely-on-their-own-when-it-comes-to-arsenic-592a54313504782cPharmaRadar360en2026-09-15T16:33:52.000ZMinnesota private well owners are largely on their own when it comes to arsenichttps://www.pharmaradar360.com/article/what-a-federal-mail-in-ballot-proposal-means-for-minnesota-voters-37e175b0fe4b7083PharmaRadar360en2026-09-15T16:33:19.000ZWhat a federal mail-in ballot proposal means for Minnesota votershttps://www.pharmaradar360.com/article/planning-to-repair-your-lawn-this-fall-here-s-what-you-need-to-know-7863c5bdc59effd1PharmaRadar360en2026-09-15T16:32:25.000ZPlanning to repair your lawn this fall? Here's what you need to knowhttps://www.pharmaradar360.com/article/jd-vance-s-catholicism-could-be-at-odds-with-maga-evangelicals-in-2028-92a05500444ddfe5PharmaRadar360en2026-09-15T16:31:56.000ZJD Vance’s Catholicism could be at odds with Maga evangelicals in 2028https://www.pharmaradar360.com/article/cafe-mondegar-among-4-mumbai-outlets-suspended-by-fda-over-food-safety-violation-198e42aafbca49fePharmaRadar360en2026-09-15T16:29:21.000ZCafe Mondegar Among 4 Mumbai Outlets Suspended by FDA Over Food Safety Violationshttps://www.pharmaradar360.com/article/government-response-to-the-thirlwall-inquiry-ff462750db59e27bPharmaRadar360en2026-09-15T16:29:00.000ZGovernment response to the Thirlwall Inquiryhttps://www.pharmaradar360.com/article/jornada-en-conmemoracion-del-dia-mundial-del-alzheimer-en-la-unlp-0662c09aeb82f613PharmaRadar360en2026-09-15T16:23:17.000ZJornada en conmemoración del Día Mundial del Alzheimer en la UNLPhttps://www.pharmaradar360.com/article/the-energy-uc-irvine-never-used-47d02add849c9ba3PharmaRadar360en2026-09-15T16:21:55.000ZThe energy UC Irvine never usedhttps://www.pharmaradar360.com/article/government-to-act-on-thirlwall-patient-safety-recommendations-8e24371ba7eef03bPharmaRadar360en2026-09-15T16:20:00.000ZGovernment to act on Thirlwall patient safety recommendationshttps://www.pharmaradar360.com/article/skyhawk-therapeutics-announces-final-fifteen-month-results-from-phase-1-2-clinic-a77c77723be25e10PharmaRadar360en2026-09-15T16:20:00.000ZSkyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patientshttps://www.pharmaradar360.com/article/cordis-project-tumour-host-interactions-in-liver-cancer-of-childhood-and-adults-777a915ed3a87482PharmaRadar360en2026-09-15T16:18:48.000ZCORDIS project: TUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTShttps://www.pharmaradar360.com/article/cordis-project-expanding-the-european-ehrxf-to-share-and-effectively-use-health-1332b9417654bb6bPharmaRadar360en2026-09-15T16:18:47.000ZCORDIS project: Expanding the European EHRxF to share and effectively use health data within the EHDShttps://www.pharmaradar360.com/article/cordis-project-virtual-brain-twin-for-personalised-treatment-of-psychiatric-diso-c73fc5eb4b7281e6PharmaRadar360en2026-09-15T16:18:31.000ZCORDIS project: Virtual Brain Twin for personalised treatment of Psychiatric Disordershttps://www.pharmaradar360.com/article/ich-kann-zeigen-was-ich-kann-schon-in-jungem-alter-bd19b1665f8d76d6PharmaRadar360en2026-09-15T16:04:36.000Z«Ich kann zeigen, was ich kann – schon in jungem Alter.»https://www.pharmaradar360.com/article/how-queueing-science-could-fix-hub-staffing-guesswork-8b1c0f65b7491859PharmaRadar360en2026-09-15T16:01:46.000ZHow Queueing Science Could Fix Hub Staffing Guessworkhttps://www.pharmaradar360.com/article/bezisterim-may-help-with-some-long-covid-symptoms-drug-s-developer-reports-in-ea-dd98e1666787e33fPharmaRadar360en2026-09-15T15:54:14.000ZBezisterim may help with some Long COVID symptoms, drug’s developer reports in early trial resultshttps://www.pharmaradar360.com/article/waltham-biotech-cuts-nearly-half-its-workforce-after-cystic-fibrosis-drug-fails-154605cf755a25bfPharmaRadar360en2026-09-15T15:53:00.000ZWaltham biotech cuts nearly half its workforce after cystic fibrosis drug failshttps://www.pharmaradar360.com/article/ori-biotech-signs-10-year-120m-deal-to-automate-commercial-cell-therapy-manufact-adbe486e7d89146bPharmaRadar360en2026-09-15T15:52:25.000ZOri Biotech signs 10-year, $120M deal to automate commercial cell therapy manufacturinghttps://www.pharmaradar360.com/article/guy-s-pharmacy-launches-medicine-collection-lockers-81967b05e661e7b2PharmaRadar360en2026-09-15T15:44:27.000ZGuy’s pharmacy launches medicine collection lockershttps://www.pharmaradar360.com/article/one-shot-against-four-dengue-strains-what-india-s-home-grown-dengiall-vaccine-co-1d2bfa01ec868da0PharmaRadar360en2026-09-15T15:40:00.000ZOne shot against four dengue strains? What India’s home-grown DengiAll vaccine could change about denguehttps://www.pharmaradar360.com/article/convenio-de-colaboracion-con-la-defensoria-de-la-ninez-bee014f00dc8db5cPharmaRadar360en2026-09-15T15:38:32.000ZConvenio de colaboración con la Defensoría de la Niñezhttps://www.pharmaradar360.com/article/la-estudiante-que-representara-al-pais-en-un-congreso-aeroespacial-visito-el-rec-6eb1e2fe926ccbe3PharmaRadar360en2026-09-15T15:38:24.000ZLa estudiante que representará al país en un congreso aeroespacial visitó el Rectoradohttps://www.pharmaradar360.com/article/constituimos-la-mesa-de-computacion-cuantica-89b47da77220d081PharmaRadar360en2026-09-15T15:37:41.000ZConstituimos la Mesa de Computación Cuánticahttps://www.pharmaradar360.com/article/science-entrepreneur-philip-goelet-joins-whitehead-institute-board-of-directors-73e5ecc85fa4e229PharmaRadar360en2026-09-15T15:35:00.000ZScience entrepreneur Philip Goelet joins Whitehead Institute Board of Directorshttps://www.pharmaradar360.com/article/ubc-researchers-awarded-1m-wall-fellowships-to-advance-human-and-ecosystem-healt-44c569f2963ac6a1PharmaRadar360en2026-09-15T15:30:00.000ZUBC researchers awarded $1M Wall Fellowships to advance human and ecosystem healthhttps://www.pharmaradar360.com/article/material-de-lectura-8517301ac515699dPharmaRadar360en2026-09-15T15:28:40.000ZMaterial de Lecturahttps://www.pharmaradar360.com/article/concursos-nodocentes-983118a1cfff9744PharmaRadar360en2026-09-15T15:28:33.000ZConcursos NoDocenteshttps://www.pharmaradar360.com/article/concursos-presidencia-0738a9ef10c73b04PharmaRadar360en2026-09-15T15:28:04.000ZConcursos Presidenciahttps://www.pharmaradar360.com/article/le-micro-de-la-maternite-un-podcast-pour-s-informer-sur-sa-grossesse-53d9972b3d11bf70PharmaRadar360en2026-09-15T15:19:31.000Z« Le Micro de la Maternité » : un podcast pour s'informer sur sa grossessehttps://www.pharmaradar360.com/article/new-partnership-creates-pathway-from-clarkson-college-to-unmc-pharmacy-programs-fbb78b823002db73PharmaRadar360en2026-09-15T15:08:11.000ZNew partnership creates pathway from Clarkson College to UNMC Pharmacy programshttps://www.pharmaradar360.com/article/fda-accepts-curi-bio-s-letter-of-intent-into-istand-program-to-qualify-3d-neurom-00b00f0510c84820PharmaRadar360en2026-09-15T15:06:15.000ZFDA Accepts Curi Bio’s Letter of Intent into ISTAND Program to Qualify 3D Neuromuscular Junction Assay as a Non-Animal Replacement for Botulinum Toxin Potency Testinghttps://www.pharmaradar360.com/article/smelling-chocolate-helped-men-complete-more-reps-without-feeling-more-tired-d83c990ebb92dc03PharmaRadar360en2026-09-15T15:03:54.000ZSmelling chocolate helped men complete more reps without feeling more tiredhttps://www.pharmaradar360.com/article/q-a-a-playbook-for-dscsa-value-beyond-compliance-eb0d87a1e73b22edPharmaRadar360en2026-09-15T15:02:21.000ZQ&A: A Playbook for DSCSA Value Beyond Compliancehttps://www.pharmaradar360.com/article/how-better-ways-of-screening-drugs-could-soon-lead-to-thousands-fewer-animal-tes-0d8c9553c4016f5cPharmaRadar360en2026-09-15T15:01:51.000ZHow better ways of screening drugs could soon lead to thousands fewer animal testshttps://www.pharmaradar360.com/article/ubiquitin-marks-abnormal-glycogen-for-destruction-to-protect-the-brain-a4e2ef403604f771PharmaRadar360en2026-09-15T15:00:00.000ZUbiquitin marks abnormal glycogen for destruction to protect the brainhttps://www.pharmaradar360.com/article/abbvie-named-official-pharmaceutical-sponsor-of-the-pga-tour-and-2026-presidents-2e56b8e582b343faPharmaRadar360en2026-09-15T14:59:17.000ZAbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaignhttps://www.pharmaradar360.com/article/abbvie-and-biolabs-university-of-toronto-open-applications-for-abbvie-biotech-in-75f7dce44dd8df60PharmaRadar360en2026-09-15T14:58:57.000ZAbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forumhttps://www.pharmaradar360.com/article/uk-advisory-panel-ukap-enquiry-form-38f5d243521e9931PharmaRadar360en2026-09-15T14:52:58.000ZUK Advisory Panel (UKAP): enquiry formhttps://www.pharmaradar360.com/article/imvax-announces-additional-data-from-phase-2b-clinical-trial-of-igv-001-in-newly-d5d0f8a72497251bPharmaRadar360en2026-09-15T14:48:12.000ZImvax Announces Additional Data from Phase 2b Clinical Trial of IGV-001 in Newly Diagnosed GBM and Provides Update on Planned Clinical Developmenthttps://www.pharmaradar360.com/article/the-biotech-industry-wrote-montana-s-right-to-try-law-now-they-re-running-the-sh-d462381332cb2633PharmaRadar360en2026-09-15T14:44:00.000ZThe biotech industry wrote Montana's right-to-try law. Now they're running the show.https://www.pharmaradar360.com/article/student-entrepreneurs-vie-for-35k-shark-tank-style-f9820b04c2555df4PharmaRadar360en2026-09-15T14:41:52.000ZStudent entrepreneurs vie for $35K, ‘Shark Tank’-stylehttps://www.pharmaradar360.com/article/intermountain-health-primary-children-s-hospitals-once-again-ranked-among-nation-002824e58ab7f154PharmaRadar360en2026-09-15T14:41:43.000ZIntermountain Health Primary Children's Hospitals Once Again Ranked Among Nation's Best in All 11 Pediatric Specialties by U.S. News & World Reporthttps://www.pharmaradar360.com/article/new-haven-biotech-raises-33m-for-cancer-drug-development-73485c033219a385PharmaRadar360en2026-09-15T14:39:41.000ZNew Haven biotech raises $33M for cancer drug developmenthttps://www.pharmaradar360.com/article/data-driven-envirolab-team-maps-the-heat-06daa6d460a43865PharmaRadar360en2026-09-15T14:38:40.000ZData-Driven EnviroLab team maps the heathttps://www.pharmaradar360.com/article/fda-hears-80-speakers-on-psychedelic-drug-therapy-standards-08469c1399c0a84aPharmaRadar360en2026-09-15T14:33:42.000ZFDA Hears 80 Speakers on Psychedelic Drug Therapy Standardshttps://www.pharmaradar360.com/article/scientists-discover-a-major-brain-shift-between-ages-50-and-75-aa4a9d132a2808caPharmaRadar360en2026-09-15T14:28:38.000ZScientists discover a major brain shift between ages 50 and 75https://www.pharmaradar360.com/article/abbvie-and-biolabs-university-of-toronto-open-applications-for-abbvie-biotech-in-4f7584c7886f13aaPharmaRadar360en2026-09-15T14:27:30.000ZAbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum